Markt oder Branche auswählen:
| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
| AVADEL PHARMACEUTICALS | 10 | 6 | -1,63 % | ||
| PRAXIS PRECISION MEDICINES | 6 | - | +30,54 % | ||
| KYMERA THERAPEUTICS | 4 | 6 | +0,59 % | ||
| IDEAYA BIOSCIENCES | 4 | 3 | -1,29 % | ||
| AMNEAL PHARMACEUTICALS | 4 | - | -1,90 % | ||
| AMGEN | 3 | 27 | -0,44 % | ||
| BIONTECH | 3 | 13 | +0,06 % | ||
| ORIC PHARMACEUTICALS | 3 | 2 | +6,88 % | ||
| OCULAR THERAPEUTIX | 3 | 1 | -1,67 % | ||
| DENALI THERAPEUTICS | 3 | - | +0,67 % |
- 24 h
- 7 Tage
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 02:06 | ORIC Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and 2L NSCLC Patients with EGFR Exon 20 Mutations at the ESMO Asia Congress 2025 | 1 | GlobeNewswire (USA) | ||
| Fr | Kymera rises on upcoming data release for eczema asset KT-621 | 1 | Seeking Alpha | ||
| Fr | Ocular Therapeutix plant Zulassungsantrag für AXPAXLI auf Basis von Phase-3-Daten | 1 | Investing.com Deutsch | ||
| Fr | Novavax, Inc. (NVAX): A Bull Case Theory | 1 | Insider Monkey | ||
| Fr | GSK ends collaboration with IDEAYA for two candidates | 7 | Seeking Alpha | ||
| Fr | Viatris: Aktionäre bestätigen Direktoren und genehmigen alle Anträge auf Hauptversammlung | 3 | Investing.com Deutsch | ||
| Fr | GlaxoSmithKline beendet Zusammenarbeit mit Ideaya Biosciences bei zwei klinischen Programmen | 11 | Investing.com Deutsch | ||
| Fr | ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| Fr | Kymera kündigt Ergebnisse der KT-621-Studie bei atopischer Dermatitis an | 3 | Investing.com Deutsch | ||
| Fr | OCULAR THERAPEUTIX, INC - 8-K, Current Report | - | SEC Filings | ||
| Fr | Kymera to announce results from KT-621 trial in atopic dermatitis | 1 | Investing.com | ||
| Fr | AMGEN INC stürzt ab - ich sehe ein gefährliches Signal! | 6 | Maximilian Berger | ||
| Fr | Spyre Therapeutics, Inc.: Spyre Therapeutics Announces Grants of Inducement Awards | 2 | GlobeNewswire (USA) | ||
| Fr | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 2 | GlobeNewswire (USA) | ||
| Fr | Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| Fr | Avadel Pharmaceuticals plc: Announcement relating to despatch of Rule 15 proposal | 1 | GlobeNewswire (USA) | ||
| Fr | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 12 | GlobeNewswire (USA) | ||
| Fr | Kymera Therapeutics, Inc.: Kymera Therapeutics to Announce KT-621 BroADen Phase 1b Atopic Dermatitis Trial Results on December 8, 2025 | 1 | GlobeNewswire (USA) | ||
| Fr | NewAmsterdam Pharma Company N.V.: NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| Fr | Viatris Inc - 8-K, Current Report | - | SEC Filings |
1 2 3 4 5 Weiter >>
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .